AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00495352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hihg-doseNRT, Low-dose NRT, bupropion
Study NCT00694941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506PO
Description: 1200mg QD / 5 years
Study NCT00649038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed
Study NCT00649038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin HCT® Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed
Study NCT04423302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-63 3 intakes per day
Description: 5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
Study NCT04423302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3 intakes per day
Description: Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
Study NCT04423302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-63 2 intakes per day
Description: 5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
Study NCT00927953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
Study NCT00927953 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - normal saline
Description: Normal Saline intravenous, volume same as active comparator, one dose at Day 0
Study NCT00825487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 621
Description: Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
Study NCT01839955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally
Study NCT01839955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinacrine dihydrochloride - Escalation dose
Description: Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
Study NCT01839955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01839955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01839955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinacrine dihydrochloride - Extension dose
Description: Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
Study NCT01921309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trinity CoC Total Hip System
Description: total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
Study NCT01921309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trinity Ceramic-on-Poly THR
Description: total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
Study NCT03946475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label.
Study NCT00675272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: hydrocortisone 50mg iv. every 6 hours
Study NCT00675272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride every 6 hours iv
Study NCT00589199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement and use of the device
Description: Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib twice daily at the protocol-defined starting dose.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal photopheresis (ECP)
Description: Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose methotrexate (MTX)
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentostatin
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT03112603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study NCT04436757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS program : Self-image and body representation
Description: The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~1. : Introduction~2. : Sensory approach workshop~3. : Self presentation and personal hygiene~4. : Organisation of well-being, planning and pictograms~5. : Becoming aware of my body, my envelope~6. : Presentation and self-esteem (photolanguage)~7. : Self-presentation in social interactions: Social codes~8. : My ideas and desires for change~9. : Places of well-being and clothing hygiene~10. : Vocational insertion devices~11. : Daring change : presence of a Socio-hairdresser~12. : The awakening of color : presence of a Socio-aesthetician~13. : Development of practice sheets and the network
Study NCT04436757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
Study NCT02192489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.3 mg Daily
Study NCT02192489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.6mg Daily
Study NCT02192489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00588016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
Study NCT03279744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radion™-pdt
Description: The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
Study NCT03904914 — intervention group
Intervention type: OTHER
Intervention: TOCI
Description: TOCI staging evaluated
Study NCT03367520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StayQuit
Description: StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
Study NCT02992795 — intervention group
Intervention type: DEVICE
Intervention: BrainPulse
Description: JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
Study NCT04029402 — intervention group
Intervention type: OTHER
Intervention: RNA sequencing
Description: Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
Study NCT00951340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: 15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
Study NCT00951340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: 15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
Study NCT00951340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional processing and interpersonal therapy
Description: 15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
Study NCT00951340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening therapy
Description: 15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
Study NCT00852852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Self-Report Assessment - Cancer (ESRA-C)
Description: The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
Study NCT03490695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
Study NCT03490695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
Study NCT01904994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POC (point-of-care) CD4+ (cluster of differentiation 4) Count
Description: Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
Study NCT01904994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated ART (antiretroviral therapy) Initiation
Description: Accelerated ART initiation for patients with POC CD4+ \< 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting
Study NCT01904994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Care and Prevention Package
Description: Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
Study NCT01904994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cellular Appointment Reminders and Follow-Up
Description: SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients.
Study NCT01904994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
Study NCT04653077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
Study NCT01642576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss counselling
Description: Diet counselling with or without sports trainers, over 8 months
Study NCT04029285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
Study NCT04029285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exergaming
Description: The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
Study NCT04765891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release therapy
Description: Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.
Study NCT04765891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Massage
Description: Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
Study NCT03769519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARICA
Description: Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
Study NCT01470326 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene
Description: For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
Study NCT03311243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy
Study NCT03311243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Study NCT03311243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical plaque control
Study NCT03311243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemical plaque control
Study NCT03345784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT03345784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03345784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT02399176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Subjects assume 10 physical postures for 30 seconds each
Study NCT00768456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5 %
Description: Local Infiltration with Ropivacaine 0.5 %